See more : Sunworks, Inc. (SUNW) Income Statement Analysis – Financial Results
Complete financial analysis of Haemonetics Corporation (HAE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Haemonetics Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Amyris, Inc. (AMRS) Income Statement Analysis – Financial Results
- Mineros S.A. (MNSAF) Income Statement Analysis – Financial Results
- DingZing Advanced Materials Inc. (6585.TW) Income Statement Analysis – Financial Results
- Greattown Holdings Ltd. (600094.SS) Income Statement Analysis – Financial Results
- Golden Ventures Leasehold Real Estate Investment Trust (GVREIT.BK) Income Statement Analysis – Financial Results
Haemonetics Corporation (HAE)
About Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.31B | 1.17B | 993.20M | 870.46M | 988.48M | 967.58M | 903.92M | 886.12M | 909.68M | 910.37M | 938.51M | 891.99M | 727.84M | 676.69M | 645.43M | 597.88M | 516.44M | 449.61M | 419.73M | 383.60M | 364.23M | 336.96M | 319.97M | 293.86M | 277.92M | 282.10M | 285.80M | 309.80M | 278.20M | 262.40M | 248.40M | 216.30M | 176.40M | 157.30M |
| Cost of Revenue | 617.51M | 553.56M | 487.69M | 472.63M | 503.97M | 550.04M | 492.02M | 507.62M | 503.80M | 475.96M | 470.14M | 463.86M | 358.60M | 321.49M | 307.95M | 289.71M | 258.72M | 222.31M | 199.20M | 185.72M | 192.11M | 182.26M | 165.14M | 126.95M | 121.70M | 124.00M | 127.10M | 137.80M | 110.50M | 103.90M | 94.20M | 88.80M | 78.50M | 0.00 |
| Gross Profit | 691.55M | 615.10M | 505.50M | 397.84M | 484.51M | 417.54M | 411.91M | 378.49M | 405.87M | 434.42M | 468.37M | 428.13M | 369.24M | 355.21M | 337.48M | 308.17M | 257.73M | 227.30M | 220.54M | 197.88M | 172.12M | 154.70M | 154.83M | 166.91M | 156.22M | 158.10M | 158.70M | 172.00M | 167.70M | 158.50M | 154.20M | 127.50M | 97.90M | 157.30M |
| Gross Profit Ratio | 52.83% | 52.63% | 50.90% | 45.70% | 49.02% | 43.15% | 45.57% | 42.71% | 44.62% | 47.72% | 49.91% | 48.00% | 50.73% | 52.49% | 52.29% | 51.54% | 49.90% | 50.56% | 52.54% | 51.58% | 47.26% | 45.91% | 48.39% | 56.80% | 56.21% | 56.04% | 55.53% | 55.52% | 60.28% | 60.40% | 62.08% | 58.95% | 55.50% | 100.00% |
| Research & Development | 54.44M | 50.13M | 46.80M | 32.86M | 30.88M | 35.71M | 39.23M | 37.56M | 45.57M | 54.19M | 54.20M | 48.64M | 36.80M | 32.66M | 26.38M | 23.86M | 24.32M | 23.88M | 26.52M | 19.99M | 17.79M | 19.51M | 19.51M | 19.04M | 14.93M | 15.10M | 17.90M | 19.00M | 18.50M | 16.70M | 15.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 424.68M | 369.48M | 335.16M | 271.49M | 295.38M | 293.78M | 313.42M | 299.23M | 320.07M | 335.19M | 363.24M | 314.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.10M | 7.20M | 4.40M | 2.70M | 4.30M | 4.50M | 3.10M | 2.50M | 3.90M | 4.50M | 3.60M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 431.78M | 376.68M | 339.56M | 274.19M | 299.68M | 298.28M | 316.52M | 301.73M | 323.97M | 339.69M | 366.84M | 318.81M | 245.26M | 213.90M | 214.48M | 198.74M | 163.12M | 137.07M | 121.35M | 118.04M | 108.45M | 97.71M | 88.87M | 86.73M | 82.76M | 86.70M | 86.90M | 92.30M | 81.80M | 75.70M | 75.90M | 77.20M | 61.00M | 0.00 |
| Other Expenses | 40.45M | 32.26M | 47.41M | 32.83M | 50.60M | 0.00 | 0.00 | -8.10M | 87.67M | 5.44M | 1.71M | -6.54M | 0.00 | -1.89M | 13.34M | 0.00 | 0.00 | -5.48M | -26.35M | -100.00K | 0.00 | 0.00 | 0.00 | 4.61M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| Operating Expenses | 526.67M | 459.06M | 433.78M | 339.88M | 330.56M | 333.99M | 355.75M | 339.28M | 369.54M | 393.88M | 421.04M | 367.45M | 282.06M | 244.66M | 240.86M | 222.60M | 187.44M | 155.48M | 121.52M | 137.93M | 126.24M | 117.22M | 108.39M | 110.39M | 122.59M | 126.40M | 127.70M | 123.60M | 113.40M | 106.10M | 102.40M | 85.70M | 68.00M | 0.00 |
| Cost & Expenses | 1.14B | 459.06M | 921.47M | 812.50M | 834.53M | 884.03M | 847.77M | 846.90M | 873.34M | 869.83M | 891.18M | 831.31M | 640.67M | 566.15M | 548.81M | 512.31M | 446.15M | 377.79M | 320.72M | 323.66M | 318.35M | 299.48M | 273.52M | 237.34M | 244.29M | 250.40M | 254.80M | 261.40M | 223.90M | 210.00M | 196.60M | 174.50M | 146.50M | 0.00 |
| Interest Income | 0.00 | 13.00M | 5.80M | 9.40M | 13.50M | 9.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 384.00K | 399.00K | 1.97M | 0.00 | 7.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.02M | 14.63M | 17.12M | 16.83M | 16.20M | 9.91M | 4.53M | 8.10M | 9.47M | 9.38M | 10.93M | 6.54M | 0.00 | 6.00K | 742.00K | 64.00K | 0.00 | 97.00K | 0.00 | 0.00 | 0.00 | 0.00 | 13.58M | 59.39M | 13.10M | 0.00 | 74.90M | 0.00 | 0.00 | 0.00 | 0.00 | 1.60M | 1.60M | 0.00 |
| Depreciation & Amortization | 97.22M | 93.31M | 97.75M | 84.29M | 110.29M | 109.42M | 89.25M | 89.73M | 89.91M | 86.05M | 81.74M | 65.48M | 49.97M | 48.15M | 43.24M | 36.46M | 31.20M | 27.50M | 25.15M | 27.58M | 30.15M | 28.43M | 25.62M | 24.50M | 24.91M | 24.60M | 22.90M | 12.30M | 13.10M | 13.70M | 10.70M | 8.50M | 7.00M | 0.00 |
| EBITDA | 265.58M | 249.34M | 178.50M | 142.25M | 264.24M | 192.96M | 153.03M | 70.35M | 45.97M | 125.72M | 127.04M | 124.58M | 139.46M | 158.23M | 125.25M | 121.53M | 101.48M | 101.10M | 124.17M | 87.52M | 77.44M | 65.91M | 72.06M | 81.02M | 73.13M | 51.20M | 53.90M | 72.00M | 67.40M | 66.10M | 62.50M | 50.30M | 36.90M | 157.30M |
| EBITDA Ratio | 20.29% | 21.34% | 17.06% | 16.34% | 26.73% | 19.94% | 16.09% | 14.55% | 13.89% | 4.45% | 5.04% | 6.80% | 11.66% | 23.51% | 15.03% | 20.74% | 19.27% | 22.23% | 22.63% | 22.78% | 20.60% | 18.85% | 25.00% | 34.44% | 23.56% | 18.15% | 26.91% | 18.30% | 23.08% | 24.43% | 24.07% | 23.16% | 20.58% | 100.00% |
| Operating Income | 164.88M | 156.03M | 80.75M | 57.96M | 153.95M | 83.55M | 56.16M | -19.38M | -43.98M | 40.54M | 47.33M | 56.44M | 88.76M | 110.55M | 83.28M | 85.57M | 70.29M | 62.75M | 99.02M | 59.94M | 45.88M | 37.48M | 36.45M | 13.42M | 33.63M | 31.70M | 31.00M | 48.40M | 54.30M | 52.40M | 51.80M | 41.80M | 29.90M | 157.30M |
| Operating Income Ratio | 12.60% | 13.35% | 8.13% | 6.66% | 15.57% | 8.63% | 6.21% | -2.19% | -4.84% | 4.45% | 5.04% | 6.33% | 12.19% | 16.34% | 12.90% | 14.31% | 13.61% | 13.96% | 23.59% | 15.63% | 12.60% | 11.12% | 11.39% | 4.57% | 12.10% | 11.24% | 10.85% | 15.62% | 19.52% | 19.97% | 20.85% | 19.33% | 16.95% | 100.00% |
| Total Other Income/Expenses | -13.02M | -14.63M | -17.12M | 14.95M | -16.20M | -9.91M | 3.48M | -8.10M | -97.14M | -9.38M | -10.93M | -6.54M | 740.00K | -467.00K | -2.01M | -565.00K | 7.02M | 9.59M | 7.86M | -102.00K | -65.00K | 1.13M | 2.06M | 3.91M | 3.25M | 969.00K | -26.50M | 2.30M | 900.00K | 100.00K | -1.00M | -1.80M | -2.20M | -157.30M |
| Income Before Tax | 151.87M | 141.40M | 63.63M | 72.91M | 87.15M | 73.63M | 59.63M | -27.48M | -53.46M | 31.17M | 36.40M | 49.90M | 89.50M | 110.08M | 81.27M | 85.00M | 77.30M | 72.34M | 106.88M | 59.84M | 45.81M | 38.61M | 38.51M | 17.33M | 27.33M | 32.60M | 4.50M | 50.70M | 55.20M | 52.50M | 50.80M | 40.00M | 27.70M | 0.00 |
| Income Before Tax Ratio | 11.60% | 12.10% | 6.41% | 8.38% | 8.82% | 7.61% | 6.60% | -3.10% | -5.88% | 3.42% | 3.88% | 5.59% | 12.30% | 16.27% | 12.59% | 14.22% | 14.97% | 16.09% | 25.46% | 15.60% | 12.58% | 11.46% | 12.03% | 5.90% | 9.83% | 11.56% | 1.57% | 16.37% | 19.84% | 20.01% | 20.45% | 18.49% | 15.70% | 0.00% |
| Income Tax Expense | 34.31M | 26.00M | 20.25M | -6.56M | 10.63M | 18.61M | 14.06M | -1.21M | 2.16M | 14.27M | 1.25M | 11.10M | 22.61M | 30.10M | 22.90M | 25.70M | 25.32M | 23.23M | 37.81M | 20.20M | 16.49M | 10.23M | 10.78M | 10.09M | 8.47M | 11.40M | 3.90M | 17.70M | 19.30M | 18.90M | 19.30M | 15.20M | 9.70M | 0.00 |
| Net Income | 117.56M | 115.40M | 43.38M | 79.47M | 76.53M | 55.02M | 45.57M | -26.27M | -55.62M | 16.90M | 35.15M | 38.80M | 66.89M | 79.98M | 58.38M | 59.30M | 51.98M | 49.11M | 69.08M | 39.64M | 29.32M | 28.38M | 30.03M | 7.24M | 19.00M | 21.10M | -24.80M | 33.00M | 35.90M | 33.60M | 31.50M | 24.80M | 18.00M | 0.00 |
| Net Income Ratio | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | 5.69% | 5.04% | -2.96% | -6.11% | 1.86% | 3.75% | 4.35% | 9.19% | 11.82% | 9.04% | 9.92% | 10.07% | 10.92% | 16.46% | 10.33% | 8.05% | 8.42% | 9.38% | 2.46% | 6.84% | 7.48% | -8.68% | 10.65% | 12.90% | 12.80% | 12.68% | 11.47% | 10.20% | 0.00% |
| EPS | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | 1.07 | 0.86 | -0.51 | -1.09 | 0.33 | 0.68 | 0.76 | 1.30 | 1.59 | 1.15 | 1.17 | 1.00 | 0.92 | 1.29 | 0.77 | 0.60 | 0.57 | 0.57 | 0.14 | 0.30 | 0.39 | -0.47 | 0.61 | 0.66 | 0.61 | 0.56 | 0.45 | 0.33 | 0.26 |
| EPS Diluted | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | 1.04 | 0.85 | -0.51 | -1.09 | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 | 1.12 | 1.14 | 0.97 | 0.89 | 1.25 | 0.75 | 0.60 | 0.56 | 0.56 | 0.14 | 0.29 | 0.39 | -0.47 | 0.60 | 0.65 | 0.59 | 0.55 | 0.44 | 0.32 | 0.25 |
| Weighted Avg Shares Out | 50.71M | 50.78M | 51.05M | 50.69M | 50.69M | 51.53M | 52.76M | 51.51M | 50.91M | 51.53M | 51.61M | 51.35M | 50.73M | 50.15M | 50.90M | 50.78M | 51.65M | 53.49M | 52.96M | 51.05M | 48.87M | 49.18M | 52.43M | 50.60M | 52.17M | 53.49M | 52.77M | 54.38M | 54.39M | 55.54M | 55.75M | 55.73M | 55.38M | 55.60M |
| Weighted Avg Shares Out (Dil) | 51.40M | 51.42M | 51.35M | 51.29M | 51.82M | 52.94M | 53.50M | 51.52M | 50.91M | 52.09M | 52.38M | 52.26M | 51.59M | 51.19M | 52.13M | 52.35M | 53.49M | 55.30M | 54.95M | 52.85M | 49.28M | 50.10M | 54.31M | 52.01M | 53.00M | 53.77M | 53.33M | 54.83M | 55.23M | 56.95M | 57.80M | 57.01M | 57.14M | 55.60M |
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Haemonetics (HAE) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.77 per share a year ago.
Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website. The...
PHG vs. HAE: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Royal Philips (PHG) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
Exploring Analyst Estimates for Haemonetics (HAE) Q4 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Haemonetics (HAE) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Haemonetics (HAE) Banks on Plasma Arm Growth Amid Rising Costs
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024
BOSTON , April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a...
HAE vs. ABT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Abbott (ABT). But which of these two stocks is more attractive to value investors?
Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval
Haemonetics' (HAE) TEG testing gives vital information that can assist doctors with better control of their patients' hemostasis.
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge
BOSTON , April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced today that it has received 510(k) clearance from the U.S. Food and...
Source: https://incomestatements.info
Category: Stock Reports